Sign in
Taking peoplePhase 2

Risedronate for dilated cardiomyopathy caused by a Troponin T gene change

Tests risedronate on heart function in adults with Troponin T K210 deletion cardiomyopathy.

Key facts

Who runs it
Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia
Where
Spain1 site in 1 countryChoose a country to see its sites
Registry title
Treatment with Risedronate for dilated cardiomyopathy due to Troponin T alteration due to K210 deletion.
Status
Recruiting
Phase
Phase 2
People taking part
5 people, planned
Started
8 Apr 2025
Planned end
31 Jul 2026
Type of study
Interventional
Record updated
22 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with dilated cardiomyopathy (an enlarged, weakened heart muscle) caused by the K210 deletion in the Troponin T gene. It tests Risedronate 10 mg/day.

Age
Older than 18 years.
Sex
All sexes can join.
Disease stage
Dilated cardiomyopathy with a left ventricular ejection fraction (LVEF, how well the heart pumps) of 50% or less.
Earlier treatment
People must not have used other investigational drugs at the time of inclusion or in the 30 days before.
Biomarker or test result
K210 deletion mutation in the Troponin T gene.

Main reasons for not taking part

  • Allergy to Risedronate or low blood calcium (hypocalcemia).
  • Severe kidney failure (eGFR < 30 ml/min/1.73m2).
  • Esophagus (food pipe) disorders that slow emptying, such as stenosis or achalasia, or Barrett's esophagus.
  • Not able to stay upright for at least 30 minutes after taking the tablet.
  • Current corticosteroid or chemotherapy treatment, or being pregnant or breastfeeding.

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Older than 18 years old
  • Dilated cardiomyopathy due to K210 deletion mutation in the Troponin T gene
  • LVEF ≤ 50%
  • Patients who have given written informed consent

Who cannot take part

  • Active treatment with corticosteroids or chemotherapy
  • Use of other investigational drugs at the time of inclusion, or during the 30 days prior to inclusion
  • Hypersensitivity to Risedronate
  • History of esophageal disorders, with delay in transit or esophageal emptying, due to example, stenosis or achalasia
  • Severe renal failure (eGFR < 30 ml/min/1.73m2)
  • Hypocalcemia
  • Barrett's esophagus
  • Inability to remain upright for at least 30 minutes after taking of the tablet
  • Pregnant or breastfeeding women

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To study whether the administration of Risedronate 10 mg/day in patients with dilated cardiomyopathy due to K210 deletion mutation in the Troponin T gene is associated with: A change in left ventricular function, measured by Echocardiogram

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Treatment with Risedronate for dilated cardiomyopathy due to Troponin T alteration due to K210 deletion.
Plain-language title
Risedronate for dilated cardiomyopathy caused by a Troponin T gene changeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
22 November 2024
Treatment with Risedronate for dilated cardiomyopathy due to Troponin T alteration due to K210 deletion. (2023-509431-29-00) – Frontlight Research